Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of Adolescents and Young Adults with children and older adults.

Cabannes-Hamy A, Boissel N, Peffault De Latour R, Lengliné E, Leblanc T, de Fontbrune FS, Raffoux E, Robin M, Xhaard A, Baruchel A, Socié G, Dhédin N.

Br J Haematol. 2018 Dec;183(5):766-774. doi: 10.1111/bjh.15650. Epub 2018 Nov 8.

PMID:
30407615
2.

Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.

Benajiba L, Alexe G, Su A, Raffoux E, Soulier J, Hemann MT, Hermine O, Itzykson R, Stegmaier K, Puissant A.

Leukemia. 2018 Nov 2. doi: 10.1038/s41375-018-0291-x. [Epub ahead of print] No abstract available.

PMID:
30390009
3.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial.

Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S.

Haematologica. 2018 Aug 3. pii: haematol.2018.188888. doi: 10.3324/haematol.2018.188888. [Epub ahead of print]

4.

A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia.

Heiblig M, Elhamri M, Thomas X, Plesa A, Raffoux E, Hayette S.

Leuk Res. 2018 Sep;72:7-11. doi: 10.1016/j.leukres.2018.07.017. Epub 2018 Jul 21. No abstract available.

PMID:
30059824
5.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

Adès L, Thomas X, Guerci Bresler A, Raffoux E, Spertini O, Vey N, Marchand T, Récher C, Pigneux A, Girault S, Deconinck E, Gardin C, Tournilhac O, Lambert JF, Chevallier P, de Botton S, Lejeune J, Dombret H, Chevret S, Fenaux P; French Belgian Swiss APL group.

Haematologica. 2018 Jul 19. pii: haematol.2018.198614. doi: 10.3324/haematol.2018.198614. [Epub ahead of print]

6.

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V.

Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14.

PMID:
29907599
7.

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P.

Haematologica. 2018 Nov;103(11):e519-e521. doi: 10.3324/haematol.2018.193151. Epub 2018 May 24. No abstract available.

8.

NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.

Prata PH, Bally C, Prebet T, Recher C, Venton G, Thomas X, Raffoux E, Pigneux A, Cluzeau T, Desoutter J, Gay J, Preudhomme C, Fenaux P, Adès L.

Haematologica. 2018 Oct;103(10):e455-e457. doi: 10.3324/haematol.2018.189886. Epub 2018 May 10. No abstract available.

9.

Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016.

Hurabielle C, Battistella M, Ram-Wolff C, Fite C, Meignin V, Rivet J, Vignon-Pennamen MD, de Risi-Pugliese T, Raffoux E, Arnulf B, Oksenhendler E, Sicre de Fontbrune F, Peffault de Latour R, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Bagot M.

Ann Dermatol Venereol. 2018 Jun - Jul;145(6-7):405-412. doi: 10.1016/j.annder.2018.01.049. Epub 2018 Apr 14.

PMID:
29661476
10.

[Renal toxicity of high-dose methotrexate].

Garcia H, Leblond V, Goldwasser F, Bouscary D, Raffoux E, Boissel N, Broutin S, Joly D.

Nephrol Ther. 2018 Apr;14 Suppl 1:S103-S113. doi: 10.1016/j.nephro.2018.02.015. French.

PMID:
29606256
11.

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.

Ali A, Penneroux J, Dal Bello R Jr, Massé A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Adès L, Puissant A, Itzykson R.

Leukemia. 2018 Aug;32(8):1856-1860. doi: 10.1038/s41375-018-0076-2. Epub 2018 Feb 26. No abstract available.

PMID:
29535430
12.

KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.

Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, Sicre de Fontbrune F, Peffault de Latour R, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M.

Br J Dermatol. 2018 Jul;179(1):197-199. doi: 10.1111/bjd.16322. Epub 2018 May 9. No abstract available.

PMID:
29315492
13.

Long-term survival following post-allograft relapse of T-cell acute lymphoblastic leukaemia: a novel approach using nelarabine and donor lymphocyte infusions.

Burley K, Wolf J, Raffoux E, Marks DI.

Bone Marrow Transplant. 2018 Mar;53(3):344-346. doi: 10.1038/s41409-017-0038-8. Epub 2017 Dec 21. No abstract available.

PMID:
29269798
14.

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.

Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, Dupriez B, Guillerm G, Raffoux E, de Fontbrune FS, Ades L, Balsat M, Chaoui D, Coppo P, Corm S, Leblanc T, Maillard N, Terriou L, Socié G, de Latour RP.

Haematologica. 2018 Feb;103(2):212-220. doi: 10.3324/haematol.2017.176339. Epub 2017 Nov 23.

15.

Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials.

Schlenk RF, Krauter J, Raffoux E, Kreuzer KA, Schaich M, Noens L, Pabst T, Vusirikala M, Bouscary D, Spencer A, Candoni A, Gil JS, Berkowitz N, Weber HJ, Ottmann O.

Haematologica. 2018 Jan;103(1):e25-e28. doi: 10.3324/haematol.2017.172411. Epub 2017 Oct 19. No abstract available.

16.

Unexpected Pneumocystis jirovecii pneumonia in patients with untreated chronic lymphocytic leukemia.

Sesé L, Rivaud E, Bron C, Leblond V, Raffoux E, Longchampt E, Cahen P, Zemoura L, Mellot F, Couderc LJ, Catherinot E; Foch Hospital Lung Immune Deficiencies study group.

Leuk Lymphoma. 2018 Apr;59(4):1004-1007. doi: 10.1080/10428194.2017.1357170. Epub 2017 Aug 3. No abstract available.

PMID:
28771054
17.

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.

Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, Rohrlich P, Ades L, Chomienne C, Auberger P, Fenaux P, Cluzeau T.

Oncotarget. 2017 Jul 18;8(29):47103-47109. doi: 10.18632/oncotarget.17482.

18.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H.

J Clin Oncol. 2017 Apr 10;35(11):1223-1230. doi: 10.1200/JCO.2016.70.4551. Epub 2017 Feb 21.

PMID:
28221862
19.

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Chevallier P, Chantepie S, Huguet F, Raffoux E, Thomas X, Leguay T, Marchand T, Isnard F, Charbonnier A, Maury S, Gallego-Hernanz MP, Robillard N, Guillaume T, Peterlin P, Garnier A, Rialland F, Le Houerou C, Goldenberg DM, Wegener WA, Béné MC, Dombret H.

Haematologica. 2017 May;102(5):e184-e186. doi: 10.3324/haematol.2016.159905. Epub 2017 Feb 2. No abstract available.

20.

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

Wang L, Raffoux E, Thomas X, Yakoub-Agha I, Bouhris JH, de Botton S, Michallet M, Quoc SN, Chantepie S, Deconinck E, Caillot D, Turlure P, Vigouroux S, Pigneux A, Huynh A, Malfuson JV, Loschi M, Socie G, Dombret H, de la Tour RP, Cluzeau T.

Leuk Res. 2017 Mar;54:12-16. doi: 10.1016/j.leukres.2017.01.002. Epub 2017 Jan 5.

PMID:
28088653
21.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, Hayette S, Braun T, Coudé MM, Terre C, Celli-Lebras K, Dombret H, Preudhomme C, Boissel N.

J Clin Oncol. 2017 Jan 10;35(2):185-193. Epub 2016 Nov 14.

PMID:
28056203
22.

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.

Ades L, Prebet T, Stamatoullas A, Recher C, Guieze R, Raffoux E, Bouabdallah K, Hunault M, Wattel E, Stalnikiewicz L, Toma A, Dombret H, Vey N, Sebert M, Gardin C, Chaffaut C, Chevret S, Fenaux P.

Haematologica. 2017 Apr;102(4):728-735. doi: 10.3324/haematol.2016.151894. Epub 2016 Dec 29.

23.

Management of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French Society of Anesthesia and Intensive Care (SFAR), the French Society of Hematology (SFH), the French Society for Hospital Hygiene (SF2H), and the French Infectious Diseases Society (SPILF).

Schnell D, Azoulay E, Benoit D, Clouzeau B, Demaret P, Ducassou S, Frange P, Lafaurie M, Legrand M, Meert AP, Mokart D, Naudin J, Pene F, Rabbat A, Raffoux E, Ribaud P, Richard JC, Vincent F, Zahar JR, Darmon M.

Ann Intensive Care. 2016 Dec;6(1):90. doi: 10.1186/s13613-016-0189-6. Epub 2016 Sep 15. Review.

24.

Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone.

Verger E, Rattarittamrong E, Letort G, Raffoux E, Cassinat B, Kiladjian JJ.

Leuk Lymphoma. 2017 Mar;58(3):749-751. doi: 10.1080/10428194.2016.1213833. Epub 2016 Aug 11. No abstract available.

PMID:
27562925
25.

New therapeutic strategies for invasive aspergillosis in the era of azole resistance: how should the prevalence of azole resistance be defined?

Alanio A, Denis B, Hamane S, Raffoux E, Peffault de la Tour R, Touratier S, Bergeron A, Bretagne S.

J Antimicrob Chemother. 2016 Aug;71(8):2075-8. doi: 10.1093/jac/dkw036. Review.

PMID:
27494830
26.

Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study.

Mariette C, Tavernier E, Hocquet D, Huynh A, Isnard F, Legrand F, Lhéritier V, Raffoux E, Dombret H, Ifrah N, Cahn JY, Thiébaut A.

Leuk Lymphoma. 2017 Mar;58(3):586-593. doi: 10.1080/10428194.2016.1204652. Epub 2016 Jul 11.

PMID:
27397551
27.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.

Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, Gomez-Roca C, Papayannidis C, Kebenko M, Paschka P, Christen R, Guarin E, Bröske AM, Baehner M, Brewster M, Walz AC, Michielin F, Runza V, Meresse V, Recher C.

Oncotarget. 2016 May 31;7(22):32532-42. doi: 10.18632/oncotarget.8687.

28.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H.

Lancet Haematol. 2016 Apr;3(4):e186-95. doi: 10.1016/S2352-3026(15)00247-1. Epub 2016 Mar 18.

PMID:
27063977
29.

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29. No abstract available.

30.

Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.

Mamez AC, Raffoux E, Chevret S, Lemiale V, Boissel N, Canet E, Schlemmer B, Dombret H, Azoulay E, Lengliné E.

Leuk Lymphoma. 2016 Oct;57(10):2281-8. doi: 10.3109/10428194.2016.1142083. Epub 2016 Feb 5.

PMID:
26849624
31.

Azole Resistance of Aspergillus fumigatus in Immunocompromised Patients with Invasive Aspergillosis.

Alanio A, Denis B, Hamane S, Raffoux E, Peffault de Latour R, Menotti J, Amorim S, Touratier S, Bergeron A, Bretagne S.

Emerg Infect Dis. 2016 Jan;22(1):157-8. doi: 10.3201/eid2201.150848. No abstract available.

32.

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.

Ravandi F, Pigneux A, DeAngelo DJ, Raffoux E, Delaunay J, Thomas X, Kadia T, Kantarjian H, Scheuenpflug J, Zhao C, Guo W, Smith BD.

Blood Cancer J. 2015 Dec 11;5:e375. doi: 10.1038/bcj.2015.103. No abstract available.

33.

Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.

Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H.

J Clin Oncol. 2016 Feb 20;34(6):572-80. doi: 10.1200/JCO.2015.61.5385. Epub 2015 Dec 7.

34.

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.

Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, Kahatt C, Raffoux E, Stathis A, Thieblemont C, Quesnel B, Cunningham D, Riveiro ME, Rezaï K.

Clin Pharmacokinet. 2016 Mar;55(3):397-405. doi: 10.1007/s40262-015-0327-6.

PMID:
26341814
35.

Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma.

Segot A, Raffoux E, Lengline E, Thieblemont C, Dombret H, Boissel N, Cluzeau T.

Ann Hematol. 2015 Nov;94(11):1859-63. doi: 10.1007/s00277-015-2475-z. Epub 2015 Aug 18.

PMID:
26280395
36.

Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.

Khaznadar Z, Boissel N, Agaugué S, Henry G, Cheok M, Vignon M, Geromin D, Cayuela JM, Castaigne S, Pautas C, Raffoux E, Lachuer J, Sigaux F, Preudhomme C, Dombret H, Dulphy N, Toubert A.

J Immunol. 2015 Sep 15;195(6):2580-90. doi: 10.4049/jimmunol.1500262. Epub 2015 Aug 5.

37.

Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study.

Denis B, Lafaurie M, Donay JL, Fontaine JP, Oksenhendler E, Raffoux E, Hennequin C, Allez M, Socie G, Maziers N, Porcher R, Molina JM.

Int J Infect Dis. 2015 Oct;39:1-6. doi: 10.1016/j.ijid.2015.07.010. Epub 2015 Jul 17.

38.

Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.

Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti AM, Sebert M, Boissel N, Robin M, Vey N, Kiladjian JJ, Dombret H, Cluzeau T.

Br J Haematol. 2016 Feb;172(4):628-30. doi: 10.1111/bjh.13516. Epub 2015 Jun 10. No abstract available.

PMID:
26061174
39.

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.

Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C.

Oncotarget. 2015 Jul 10;6(19):17698-712.

40.

New Short Tandem Repeat-Based Molecular Typing Method for Pneumocystis jirovecii Reveals Intrahospital Transmission between Patients from Different Wards.

Gits-Muselli M, Peraldi MN, de Castro N, Delcey V, Menotti J, Guigue N, Hamane S, Raffoux E, Bergeron A, Valade S, Molina JM, Bretagne S, Alanio A.

PLoS One. 2015 May 1;10(5):e0125763. doi: 10.1371/journal.pone.0125763. eCollection 2015.

41.

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lhéritier V, Chevret S, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2015 Jun 11;125(24):3711-9. doi: 10.1182/blood-2015-02-627935. Epub 2015 Apr 15. Erratum in: Blood. 2015 Sep 3;126(10):1261.

42.

Myelodysplasia Cutis Versus Leukemia Cutis.

Osio A, Battistella M, Feugeas JP, Cuccuini W, Noguera ME, Petrella T, Raffoux E, Janin A, Pennamen V.

J Invest Dermatol. 2015 Sep;135(9):2321-2324. doi: 10.1038/jid.2015.146. Epub 2015 May 10. No abstract available.

43.

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group.

Cancer. 2015 Jul 15;121(14):2393-9. doi: 10.1002/cncr.29389. Epub 2015 Apr 6.

44.

Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells.

El Hajj H, Dassouki Z, Berthier C, Raffoux E, Ades L, Legrand O, Hleihel R, Sahin U, Tawil N, Salameh A, Zibara K, Darwiche N, Mohty M, Dombret H, Fenaux P, de Thé H, Bazarbachi A.

Blood. 2015 May 28;125(22):3447-54. doi: 10.1182/blood-2014-11-612416. Epub 2015 Mar 23.

45.

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM.

Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, Cahn JY, Delmer A, Wattel E, Vigouroux S, Bay JO, Cornillon J, Huynh A, Nguyen S, Rubio MT, Vincent L, Maillard N, Charbonnier A, de Latour RP, Reman O, Dombret H, Fenaux P, Socié G.

Leukemia. 2015 Jul;29(7):1496-501. doi: 10.1038/leu.2015.37. Epub 2015 Feb 13.

PMID:
25676424
46.

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

Chevallier P, Huguet F, Raffoux E, Etienne A, Leguay T, Isnard F, Robillard N, Guillaume T, Delaunay J, Charbonnier A, Pigneux A, Peterlin P, Bené MC, Wegener WA, Goldenberg DM, Dombret H.

Haematologica. 2015 Apr;100(4):e128-31. doi: 10.3324/haematol.2014.120220. Epub 2014 Dec 31. No abstract available.

47.

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Peterlin P, Renneville A, Ben Abdelali R, Nibourel O, Thomas X, Pautas C, de Botton S, Raffoux E, Cayuela JM, Boissel N, Terré C, Celli-Lebras K, Castaigne S, Preudhomme C, Gardin C, Dombret H.

Haematologica. 2015 May;100(5):e196-9. doi: 10.3324/haematol.2014.115576. Epub 2014 Dec 31. No abstract available.

48.

Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.

Rea D, Mirault T, Raffoux E, Boissel N, Andreoli AL, Rousselot P, Dombret H, Messas E.

Leukemia. 2015 May;29(5):1206-9. doi: 10.1038/leu.2014.342. Epub 2014 Dec 8. No abstract available.

PMID:
25482133
49.

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.

Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).

Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7.

PMID:
25449687
50.

Human metapneumovirus pneumonia in patients with hematological malignancies.

Godet C, Le Goff J, Beby-Defaux A, Robin M, Raffoux E, Arnulf B, Roblot F, Frat JP, Maillard N, Tazi A, Bergeron A.

J Clin Virol. 2014 Dec;61(4):593-6. doi: 10.1016/j.jcv.2014.08.019. Epub 2014 Sep 1.

PMID:
25440914

Supplemental Content

Loading ...
Support Center